23:33 , Nov 2, 2018 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least nine profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 1Q; (B) Fiscal 4Q Company Date Pre/post mkt 3Q18 EPS est 3Q17 EPS Expected chg Bausch...
16:04 , Oct 25, 2018 |  BC Innovations  |  Translation in Brief

Classifying BRCA1 mutations

University of Washington researchers have characterized the clinical consequences of nearly 4,000 variants in the tumor suppressor gene BRCA1 using saturation genome editing. The results provide interpretation of variants with previously uncertain significance and will...
18:10 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

After three deals, FDA approval, talazoparib joins PARP party

FDA approved Talzenna talazoparib from Pfizer Inc. (NYSE:PFE) to treat germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer, making it the second PARP inhibitor approved for the indication. The approval comes well ahead of...
22:50 , Oct 16, 2018 |  BC Extra  |  Company News

After three deals, FDA approval talazoparib joins PARP party

FDA approved Talzenna talazoparib from Pfizer Inc. (NYSE:PFE) to treat germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer, making it the second PARP inhibitor approved for the indication. The approval comes well ahead of...
00:16 , Sep 29, 2018 |  BioCentury  |  Politics, Policy & Law

Patent law 101

The director of the U.S. Patent and Trademark Office, Andrei Iancu, said last week that a fundamental aspect of patent law that affects life science patents is completely screwed up, and because Congress can’t be...
03:02 , Jun 30, 2018 |  BioCentury  |  Finance

Smitten by SMID-caps

Risk is pervasive heading into the third quarter and choppy waters are expected, but 13 buysiders told BioCentury they’re not afraid to stay the course. A politically charged environment is likely to intensify as the...
00:06 , May 5, 2018 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 11 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 3Q; (B) 12-month EPS; Source: Yahoo! Finance, Financial Times, company websites Company Date Pre/post mkt 1Q18...
18:47 , Mar 16, 2018 |  BC Week In Review  |  Financial News

Cyteir raises $29M series B

Cyteir Therapeutics Inc. (Cambridge, Mass.) raised $29 million in a series B round led by Venrock on March 8. Existing investor Celgene Corp. (NASDAQ:CELG) participated alongside new investors Lightstone Ventures and DROIA Oncology Ventures. Cyteir...
19:51 , Mar 8, 2018 |  BC Extra  |  Financial News

Cyteir raises $29M series B

Cyteir Therapeutics Inc. (Cambridge, Mass.) raised $29 million in a series B round led by Venrock. Existing investor Celgene Corp. (NASDAQ:CELG) participated alongside new investors Lightstone Ventures and DROIA Oncology Ventures. Cyteir plans to begin...
23:09 , Feb 2, 2018 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 12 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 3Q; (B) Nine-month EPS; (C) Fiscal 2Q; (D) During trading hours in Europe; premarket on U.S....